NASDAQ:CLSD

Clearside Biomedical - CLSD Stock Forecast, Price & News

$1.54

-0.05 (-3.14%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.51
▼
$1.60
50-Day Range: $1.30
▼
$1.83
52-Week Range: $1.26
▼
$7.73

Volume: 94,532 shs
Average Volume: 132,141 shs
Market Capitalization: $92.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Clearside Biomedical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 419.5% Upside
$8.00 Price Target
Short Interest: Healthy
0.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 15 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.36) to ($0.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

218th out of 1,125 stocks

Pharmaceutical Preparations Industry

98th out of 554 stocks

3.5

Analyst's Opinion

Consensus Rating
Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Clearside Biomedical has a forecasted upside of 419.5% from its current price of $1.54.
Amount of Analyst Coverage
Clearside Biomedical has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.97% of the float of Clearside Biomedical has been sold short.
Short Interest Ratio / Days to Cover
Clearside Biomedical has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Clearside Biomedical has recently decreased by 20.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Clearside Biomedical does not currently pay a dividend.
Dividend Growth
Clearside Biomedical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLSD.

3.7

News and Social Media Coverage

News Sentiment
Clearside Biomedical has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Clearside Biomedical this week, compared to 1 article on an average week.
Search Interest
7 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
MarketBeat Follows
5 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clearside Biomedical insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.00% of the stock of Clearside Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.71% of the stock of Clearside Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Clearside Biomedical are expected to grow in the coming year, from ($0.36) to ($0.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clearside Biomedical is -51.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clearside Biomedical is -51.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Clearside Biomedical has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Clearside Biomedical (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical Stock Down 3.1 %

Shares of NASDAQ:CLSD opened at $1.54 on Tuesday. The company has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.71. Clearside Biomedical has a 12 month low of $1.26 and a 12 month high of $7.73.

Clearside Biomedical (NASDAQ:CLSD - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Clearside Biomedical had a negative net margin of 5.54% and a negative return on equity of 5.60%. During the same period in the prior year, the business earned ($0.11) earnings per share. Research analysts expect that Clearside Biomedical will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. StockNews.com upgraded Clearside Biomedical from a "hold" rating to a "buy" rating in a research report on Wednesday, August 10th. HC Wainwright cut their price objective on shares of Clearside Biomedical from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday, August 10th. Finally, TheStreet lowered shares of Clearside Biomedical from a "c" rating to a "d+" rating in a research note on Wednesday, May 11th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $8.00.

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

August 16, 2022 | americanbankingnews.com

Wedbush Weighs in on Clearside Biomedical, Inc.'s FY2022 Earnings (NASDAQ:CLSD)

August 14, 2022 | americanbankingnews.com

HC Wainwright Trims Clearside Biomedical (NASDAQ:CLSD) Target Price to $5.00

August 12, 2022 | americanbankingnews.com

Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Buy at StockNews.com

August 11, 2022 | finance.yahoo.com

These Analysts Think Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Sales Are Under Threat

August 9, 2022 | seekingalpha.com

Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript

August 9, 2022 | finance.yahoo.com

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022 | finance.yahoo.com

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

August 3, 2022 | finance.yahoo.com

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

July 31, 2022 | americanbankingnews.com

Wedbush Weighs in on Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD)

July 27, 2022 | finance.yahoo.com

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

July 26, 2022 | msn.com

Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022

July 26, 2022 | finance.yahoo.com

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

July 9, 2022 | finance.yahoo.com

Here's What Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Shareholder Ownership Structure Looks Like

July 7, 2022 | finance.yahoo.com

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

June 14, 2022 | finance.yahoo.com

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

June 8, 2022 | finance.yahoo.com

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

May 11, 2022 | seekingalpha.com

Clearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript

May 11, 2022 | finance.yahoo.com

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

May 11, 2022 | finance.yahoo.com

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022 | seekingalpha.com

Clearside Biomedical Q1 2022 Earnings Preview

May 5, 2022 | finance.yahoo.com

Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology

April 29, 2022 | finance.yahoo.com

Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022

April 11, 2022 | finance.yahoo.com

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?

March 28, 2022 | nasdaq.com

Bausch + Lomb, Clearside Biomedical Launch XIPERE For Macular Edema Associated With Uveitis In U.S.

March 15, 2022 | finance.yahoo.com

Clearside Stock Is up Over 80% In Three Trading Days. How Much Higher Can It Go?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Company Calendar

Last Earnings: 8/09/2022
Today: 8/16/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLSD
CUSIP: N/A
CIK: 1539029
Web: www.clearsidebio.com
Phone: (678) 270-3631
Fax: 678-270-4033
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +419.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $380,000.00
Net Margins: -5.54%
Pretax Margin: 0.28%
Return on Equity: -5.60%
Return on Assets: -4.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.49
Quick Ratio: 8.49

Sales & Book Value

Annual Sales: $29.58 million
Price / Sales: 3.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.64 per share
Price / Book: 2.41

Miscellaneous

Outstanding Shares: 60,150,000
Free Float: 52,932,000
Market Cap: $92.63 million
Optionable: Optionable
Beta: 1.90

Key Executives

Dr. George M. Lasezkay J.D. (Age 70)
Pharm.D., Pharma.D., Pres, CEO & Director
Comp: $836k
Mr. Charles A. Deignan (Age 58)
Chief Financial Officer
Comp: $510.81k
Dr. Thomas A. Ciulla M.B.A. (Age 58)
M.D., Chief Medical Officer & Chief Devel. Officer
Comp: $589.77k
Ms. Jenny R. Kobin (Age 55)
Head of Investor Relations
Mr. Leslie B. Zacks (Age 53)
Gen. Counsel, Chief Compliance Officer & Sec.
Mr. Rick McElheny
VP of Corp. Devel.
Ms. Susan L. Coultas Ph.D.
Chief Clinical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLSD Stock - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings or view top-rated stocks.
What is Clearside Biomedical's stock price forecast for 2022?: 3 equities research analysts have issued 1 year price objectives for Clearside Biomedical's shares. Their CLSD share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 419.5% from the stock's current price.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts.
How have CLSD shares performed in 2022?: Clearside Biomedical's stock was trading at $2.75 on January 1st, 2022. Since then, CLSD shares have decreased by 44.0% and is now trading at $1.54.
View the best growth stocks for 2022 here.
When is Clearside Biomedical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CLSD earnings forecast.
How were Clearside Biomedical's earnings last quarter?: Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its earnings results on Tuesday, August, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). Clearside Biomedical had a negative trailing twelve-month return on equity of 5.60% and a negative net margin of 5.54%. During the same period last year, the firm earned ($0.11) earnings per share.
What other stocks do shareholders of Clearside Biomedical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

When did Clearside Biomedical IPO?: (CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
What is Clearside Biomedical's stock symbol?: Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
Who are Clearside Biomedical's major shareholders?: Clearside Biomedical's stock is owned by a number of retail and institutional investors. Top institutional investors include Carmignac Gestion (3.97%), Renaissance Technologies LLC (1.34%), Assenagon Asset Management S.A. (1.26%), Millennium Management LLC (0.51%), Northern Trust Corp (0.15%) and Franklin Resources Inc. (0.13%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends.
How do I buy shares of Clearside Biomedical?: Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Clearside Biomedical's stock price today?: One share of CLSD stock can currently be purchased for approximately $1.54.
How much money does Clearside Biomedical make?: Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $92.63 million and generates $29.58 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis.
How can I contact Clearside Biomedical?: Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.

This page (NASDAQ:CLSD) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Clearside Biomedical - CLSD Stock Forecast, Price & News

Clearside Biomedical MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month